Rochester,NY 7/11/2009 9:12:54 PM
Week End Stock Report - PPDI - Premarket roundup: Danaher, Yahoo - Sourced WhisperFromWallStreet.com
Pharmaceutical Product Development Inc.
Week End Stock Report - PPDI - Premarket roundup: Danaher, Yahoo - Sourced WhisperFromWallStreet.com
Pharmaceutical Product Development Inc. PPDI
.Lower growth spelled trouble for Danaher Corp. in the second quarter, but the manufacturer of bar code readers, medical products and hand tools should see increased profit next year, an analyst said .
An analyst upgraded Yahoo Inc. in light of coming organizational changes that could make the Internet-search giant more efficient and competitive in its product offerings.
An analyst lifted Blue Nile Inc.'s rating, citing the online jewelry retailer's appealing stock price.
A Deutsche Bank analyst upgraded shares of Pharmaceutical Product Development Inc., saying the contract drug research company's stock price is inexpensive, and business from major drugmakers is likely to increase.
Last Trade: 21.07
Day's Range: 21.02 - 22.30
52wk Range: 17.97 - 45.72
Volume: 2,796,907
ABOUT - Pharmaceutical Product Development Inc.
Pharmaceutical Product Development, Inc. (PPD), a contract research organization, provides drug discovery and development services, post-approval expertise, and compound partnering programs. The company operates in two segments: Discovery Sciences and Development. The Discovery Sciences segment offers various preclinical services, including preclinical program design, preclinical oncology research models, toxicology consulting, laboratory services, and technical writing and regulatory submissions; biomarker discovery and patient sample analysis; and compound collaboration programs. The Development segment provides a range of development services, including strategic product development solutions; Phase I clinical testing; laboratory services, such as testing services with customized results databases for companies engaged in clinical drug development, as well as government-funded studies; and Phases II-IV clinical trial management services primarily comprising study protocol and case report form design, site and investigator recruitment, patient enrollment and study feasibility, interactive voice and/or Web response systems, investigative product services, study monitoring and data collection, government services, data management and biostatistical analysis, medical writing and regulatory services, and post-approval services.
---
During 2009 we have sent 40+ alerts with an average gain of over 80%. Below are a few alerts sent only to our whisperfromwallstreet.com members.
SPNG 1800%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up now to receive free stock alerts
---
Please Read Our Disclaimer at http://whisperfromwallstreet.com/disclaimer.php
